全国药品集采中标药品和中选企业异常探测  

Detecting the Abnormalities of the Selected Drugs and Enterprises in National Centralized Procurement of Drugs

作　　者：牛奔[1,2] 刘玺鲲[1,2] 柴语鹃 蚁文洁 NIU Ben;LIU Xikun;CHAI Yujuan;YI Wenjie(School of Management,Shenzhen University,Shenzhen Guangdong 518060,China;不详)

机构地区：[1]深圳大学管理学院,广东深圳518060 [2]深圳大学大湾区国际创新学院,广东深圳518060 [3]深圳大学医学部生物医学工程学院,广东深圳518060

出　　处：《卫生经济研究》2025年第3期55-58,共4页

基　　金：国家自然科学基金重点项目“数智驱动的医保资源优化配置模式与政策研究”(72334004);国家自然科学基金青年科学基金项目“跨问题群智优化算法模型构建与算法研究”(72401202);深圳市科创委高校稳定支持面上项目“无人机医疗资源智能调度优化”(20231120174835002)。

摘　　要：第九批全国药品集中带量采购共有41种中标药品,其中国家首年支付总额实际值与理想值差额处于异常值范围和临界值范围的各有5种;处于异常值范围的5种中标药品对应的中选企业共30家,其中首年销售额实际值与理想值的差额处于异常值范围的有14家。对此,可通过构建“0-1”规划模型,加强对中标药品和中选企业的异常探测,对不同支付额范围的中标药品实施差异化监管策略,多部门协调联动,确保全国药品集采的高度公平、透明与合规,在保障公众利益的同时,提升医疗保障体系的整体效能。There are 41 selected drugs in the ninth batch of national centralized volume-based procurement of drugs,among which 5 of them are in the range of outliers and 5 of them are in the range of critical values in terms of the difference between the actual and ideal payment amounts in the first year.There are 30 selected enterprises corresponding to the 5 selected drugs in the range of outliers,and 14 of them are in the range of outliers.In this regard,the"0-1"planning model should be constructed to strengthen the detection of abnormal situations in the selected drugs and enterprises,implement differentiated supervision strategies for the selected drugs with different payment ranges,and coordinate and linkage among multiple departments to ensure the high degree of fairness,transparency and compliance of national centralized procurement of drugs.While safeguarding the public interest,the overall effectiveness of the medical security system has been improved.

关 键 词：药品集中带量采购 “0-1”规划模型 中标药品 中选企业 异常探测 

分 类 号：R95[医药卫生—药学]